SJF Hartman, RJ Brüggemann, L Orriëns, N Dia… - Clinical …, 2020 - Springer
Background Pharmacokinetics (PK) are severely altered in critically ill patients due to changes in volume of distribution (Vd) and/or drug clearance (Cl). This affects the target …
WX Xu, Q Qu, XQ Teng, HH Zhuang, SF Liu… - European Journal of …, 2024 - Springer
The effect of renal functional status on drug metabolism is a crucial consideration for clinicians when determining the appropriate dosage of medications to administer. In critically …
E Dhont, T Van Der Heggen, A De Jaeger… - Pediatric …, 2020 - Springer
Many critically ill patients display a supraphysiological renal function with enhanced renal perfusion and glomerular hyperfiltration. This phenomenon described as augmented renal …
Objectives: Augmented renal clearance (ARC) is a state of enhanced renal function commonly observed in 30%–65% of critically ill patients despite normal serum creatinine …
T Van Der Heggen, E Dhont, H Peperstraete… - Pediatric …, 2019 - Springer
Background Augmented renal clearance (ARC), an increase in kidney function with enhanced elimination of circulating solute, has been increasingly recognized in critically ill …
SN Avedissian, E Bradley, D Zhang… - Pediatric Critical Care …, 2017 - journals.lww.com
Objectives: The objectives of this study were to: 1) evaluate the prevalence of augmented renal clearance in critically ill pediatric patients using vancomycin clearance; 2) derive the …
M Gijsen, D Vlasselaers, I Spriet, K Allegaert - Antibiotics, 2021 - mdpi.com
Children show important developmental and maturational changes, which may contribute greatly to pharmacokinetic (PK) variability observed in pediatric patients. These PK …
JJ Cies, WS Moore, A Enache… - The Journal of …, 2017 - meridian.allenpress.com
OBJECTIVE This study aims to describe the population pharmacokinetics and pharmacodynamic target attainment of meropenem in critically ill children. METHODS The …
M Rapp, S Urien, F Foissac, A Béranger… - European Journal of …, 2020 - Springer
Purpose We aimed to develop a meropenem population pharmacokinetic (PK) model in critically ill children and simulate dosing regimens in order to optimize patient exposure …